PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 22, 2024Cancer Research

Abstract 3212: Development of a Trop2/CD3 bispecific antibody with modulated Trop2 binding affinity as a novel immunotherapy for advanced gastrointestinal cancer treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

COChui Yee OPWPo Yee WongKCKronos Chow

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

O et al. (2024) studied this question.

synapsesocial.com/papers/68e72e1db6db6435876a724bhttps://doi.org/10.1158/1538-7445.am2024-3212
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 5635: Rational design of a bispecific ADC targeting ITGB4 and TROP2 for co-expressing solid tumors2026
  2. 2Abstract 3136: Towards development of a novel biparatopic trop2-ADC2024 · 1 citations
  3. 3Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer2026
  4. 4Abstract 5819: An anti-TROP2-CPT113 ADC, exhibits potent targeted antitumor activity and favorable pharmacokinetic properties2024
  5. 5Abstract 3133: A novel bispecific antibody-drug conjugate targeting HER2 and Trop-2 displays potent antitumor activity in a variety of tumor models with promising preclinical characteristics2024 · 2 citations